Dr. Bourla is CEO of Pfizer. He headed the trailblazing effort to develop a vaccine and antiviral drug against SARS-CoV-2, the virus that causes COVID-19. The vaccine, which is helping to end the coronavirus crisis, is expected to serve as a model for the development of a wide range of future mRNA-based treatments. During his more than 25 years at Pfizer, he has held several senior global positions across a range of markets and disciplines. Before becoming CEO, he served as COO, overseeing commercial strategy, manufacturing, and global product development. Previously, he served as group president of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. He also created the Patient and Health Impact group, dedicated to increasing patient access, demonstrating the value of Pfizer’s medicines, and broader business model innovation. Prior to that, he was president and GM of the Established Products business. Dr. Bourla is a Doctor of Veterinary Medicine with a PhD from the Veterinary School of Aristotle University and began his Pfizer career in 1993 in the Animal Health division. In 2020, Dr. Bourla was ranked America’s top CEO in the pharmaceuticals sector by Institutional Investor magazine. He is on the executive committee of the Partnership for New York City, a vice president of the IFPMA, a trustee of the U.S. Council for International Business, and a director on multiple boards, including Pfizer Inc., the Pfizer Foundation, PhRMA, and Catalyst – and a trustee of the United States Council for International Business. In addition, Dr. Bourla is a member of the Business Roundtable and the Business Council.